BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#141 of 347

Keay Nakae

Chardan Capital · Equity Research Analyst
EstablishedRating since 2020No new ratings since May 2025

Analyst rating accuracy & track record

Keay Nakae is an equity research analyst at Chardan Capital. Bullish Whales has scored 58 of their stock calls across 15 companies. Their picks beat their sector 38% of the time over the next 12 months, and their price targets were reached 40% of the time within a year.

Win % vs sector
38%
PT Hit % (12mo)
40%
Avg sector-excess
−4.4%
Scored calls
58
Tickers
15
Tier
Established

Track record

Bullish Whales has scored 58 of Keay Nakae's stock calls across 15 companies, dating back to 2020. Their rated stocks beat their own sector 38% of the time over the next 12 months. On a typical call, a Nakae pick returned −4.4% more than its sector over the following year.

Of the scored calls, 52 were bullish (Buy) and 6 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
KRROKorro Bio, Inc.
Buy$25.00May 2025−36.6%Hit
ARWRArrowhead Pharmaceuticals Inc
Buy$60.00May 2025+406.4%Hit
SLNSilence Therapeutics PLC
Buy$35.00May 2025+80.1%Miss
IBIOiBio, Inc. Common Stock
Buy$5.00May 2025+98.9%Miss
IBIOiBio, Inc. Common Stock
Buy$5.00May 2025+79.3%Miss
KRROKorro Bio, Inc.
Buy$25.00Apr 2025−13.2%Hit
ABUSArbutus Biopharma Corp
Buy$5.00Mar 2025+23.0%Hit
GANXGain Therapeutics Inc
Buy$6.00Mar 2025−6.0%Miss
MCRBSeres Therapeutics Inc
Buy$1.25Mar 2025−41.1%Hit
PRQRProQR Therapeutics BV
Buy$4.00Mar 2025−1.2%Miss
PRQRProQR Therapeutics BV
Buy$4.00Dec 2024−28.9%Miss
SLNSilence Therapeutics PLC
Buy$55.00Dec 2024−11.9%Miss
ABUSArbutus Biopharma Corp
Buy$5.00Nov 2024+14.4%Hit
SLNSilence Therapeutics PLC
Buy$55.00Nov 2024−55.2%Miss
MCRBSeres Therapeutics Inc
Buy$1.25Nov 2024+34.0%Miss
FEMYFemasys Inc
Buy$8.00Nov 2024−23.2%Miss
ABUSArbutus Biopharma Corp
Buy$4.50Nov 2024+19.4%Hit
ALURAllurion Technologies, Inc.
Buy$2.50Aug 2024−77.3%Miss
SLNSilence Therapeutics PLC
Buy$55.00Aug 2024−55.1%Miss
MCRBSeres Therapeutics Inc
Buy$1.25Aug 2024+6.0%Hit
FEMYFemasys Inc
Buy$10.00Aug 2024−21.8%Miss
GANXGain Therapeutics Inc
Buy$6.00Aug 2024+66.9%Miss
SLNSilence Therapeutics PLC
Buy$55.00Jun 2024−63.6%Miss
ABUSArbutus Biopharma Corp
Buy$4.00Jun 2024+9.3%Hit
IBIOiBio, Inc. Common Stock
Buy$5.00Jun 2024−59.8%Hit
IBIOiBio, Inc. Common Stock
Buy$5.00May 2024−61.6%Hit
ALURAllurion Technologies, Inc.
Buy$5.00May 2024−84.6%Miss
PRQRProQR Therapeutics BV
Buy$2.50May 2024−16.0%Hit
MCRBSeres Therapeutics Inc
Buy$6.00May 2024−61.4%Miss
ABUSArbutus Biopharma Corp
Buy$4.00May 2024+26.1%Hit
ALURAllurion Technologies, Inc.
Buy$5.00Apr 2024−91.2%Miss
FEMYFemasys Inc
Buy$12.00Apr 2024−30.3%Miss
GANXGain Therapeutics Inc
Buy$6.00Mar 2024−44.8%Miss
FEMYFemasys Inc
Buy$12.00Mar 2024−5.6%Miss
PRQRProQR Therapeutics BV
Buy$2.50Mar 2024−35.3%Hit
MCRBSeres Therapeutics Inc
Buy$8.00Mar 2024−28.4%Miss
ABUSArbutus Biopharma Corp
Buy$4.00Mar 2024+22.2%Hit
PRQRProQR Therapeutics BV
Buy$2.00Nov 2023+136.2%Hit
SYBXSynlogic Inc
Buy$6.00Aug 2023+162.4%Miss
MESOMesoblast Ltd
Sell$1.50Aug 2023−95.7%Hit
ABUSArbutus Biopharma Corp
Buy$6.00Aug 2023+61.0%Miss
SABSSAB Biotherapeutics Inc
Buy$3.00Jun 2023−75.9%Miss
SYBXSynlogic Inc
Buy$6.00Jun 2023+169.5%Miss
MESOMesoblast Ltd
Sell$2.00May 2023−6.1%Hit
MCRBSeres Therapeutics Inc
Buy$10.00Apr 2023−87.7%Miss
SABSSAB Biotherapeutics Inc
Buy$3.00Apr 2023−59.2%Miss
SYBXSynlogic Inc
Buy$5.50Mar 2023+163.5%Hit
MCRBSeres Therapeutics Inc
Buy$12.00Mar 2023−100.8%Miss
MESOMesoblast Ltd
Sell$2.50Mar 2023+84.2%Hit
SYBXSynlogic Inc
Buy$7.00Nov 2022+150.0%Miss
Go to

Keay Nakae: analyst track record FAQ

Is Keay Nakae a good stock analyst?

Yes, by track record. Keay Nakae ranks number 141 of 347 of the analysts Bullish Whales scores, with a BW Score of 37 out of 100. Past results do not guarantee future ones.

What is Keay Nakae's win rate?

Keay Nakae's win rate is 38%. Across 58 scored calls, their rated stocks beat their sector 38% of the time over the next 12 months. On a typical call they returned −4.4% more than the sector.

What stocks and sectors does Keay Nakae cover?

Keay Nakae covers 15 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Keay Nakae's price targets accurate?

Keay Nakae's price targets are reached within 12 months 40% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Keay Nakae's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Keay Nakae rank among Wall Street analysts?

Keay Nakae ranks number 141 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30